CNR Institutional Research Information System

PINNA, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.906
NA - Nord America 1.458
EU - Europa 1.442
SA - Sud America 478
AF - Africa 40
OC - Oceania 3
Totale 6.327
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.402
SG - Singapore 1.162
IT - Italia 1.093
CN - Cina 760
BR - Brasile 413
HK - Hong Kong 297
VN - Vietnam 259
KR - Corea 162
FR - Francia 152
JP - Giappone 59
IN - India 48
NL - Olanda 44
BD - Bangladesh 31
GB - Regno Unito 31
AR - Argentina 27
FI - Finlandia 27
IL - Israele 25
DE - Germania 20
CA - Canada 19
MX - Messico 18
IQ - Iraq 16
ID - Indonesia 14
TR - Turchia 14
ZA - Sudafrica 13
EC - Ecuador 12
UZ - Uzbekistan 11
RU - Federazione Russa 10
PY - Paraguay 9
AT - Austria 8
ES - Italia 8
MA - Marocco 7
SA - Arabia Saudita 7
SE - Svezia 7
UA - Ucraina 7
CO - Colombia 6
KE - Kenya 6
LT - Lituania 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
EG - Egitto 4
PH - Filippine 4
PK - Pakistan 4
PL - Polonia 4
AZ - Azerbaigian 3
BG - Bulgaria 3
BH - Bahrain 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
LB - Libano 3
OM - Oman 3
PE - Perù 3
TH - Thailandia 3
TN - Tunisia 3
BY - Bielorussia 2
BZ - Belize 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EE - Estonia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
MY - Malesia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AU - Australia 1
DK - Danimarca 1
GE - Georgia 1
GR - Grecia 1
IE - Irlanda 1
KG - Kirghizistan 1
MD - Moldavia 1
NI - Nicaragua 1
NO - Norvegia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
TW - Taiwan 1
TZ - Tanzania 1
VC - Saint Vincent e Grenadine 1
ZW - Zimbabwe 1
Totale 6.327
Salva come PNG Salva come JPEG
Città #
Santa Clara 760
Singapore 689
Cagliari 613
Hefei 384
Hong Kong 292
Seoul 160
Rome 157
Lauterbourg 136
San Jose 136
Beijing 119
Ho Chi Minh City 83
Hanoi 71
Ashburn 68
Uta 53
Los Angeles 51
Dallas 45
Sassoferrato 43
Tokyo 36
São Paulo 30
Minamishinagawa 23
San Benedetto del Tronto 22
Helsinki 20
Rio de Janeiro 19
Bengaluru 18
Florence 17
Naples 15
Sesto Fiorentino 14
Vaglia 14
Buffalo 13
New York 13
Tashkent 11
Matera 10
Biên Hòa 9
Sassari 9
Brasília 8
Da Nang 8
Guarulhos 8
Haiphong 8
Milan 8
Olbia 8
Porto Alegre 8
Baghdad 7
Belo Horizonte 7
Frankfurt am Main 7
Lappeenranta 7
Nuoro 7
Nuremberg 7
Phoenix 7
Santo André 7
Cabras 6
City of London 6
Dhaka 6
Manaus 6
Nairobi 6
Stockholm 6
Campinas 5
Cosenza 5
Erbil 5
Giulianova 5
Hải Dương 5
Istanbul 5
Johannesburg 5
Nha Trang 5
Poplar 5
Quartu Sant'Elena 5
Quận Bình Thạnh 5
Salvador 5
Santiago de Cali 5
Thái Bình 5
Turin 5
Brescia 4
Chennai 4
Council Bluffs 4
Curitiba 4
Denver 4
Feira de Santana 4
Guangzhou 4
Guayaquil 4
Jakarta 4
London 4
Mauá 4
Miami 4
Montreal 4
Nova Iguaçu 4
Orem 4
Philadelphia 4
Quito 4
Ribeirão Preto 4
San José 4
Seattle 4
Sorocaba 4
Thái Nguyên 4
Toronto 4
Uberlândia 4
Udine 4
Volla 4
Warsaw 4
Amsterdam 3
Baku 3
Brooklyn 3
Totale 4.493
Salva come PNG Salva come JPEG
Nome #
Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease 1.073
Genes implicated in familial parkinson's disease provide a dual picture of nigral dopaminergic neurodegeneration with mitochondria taking center stage 85
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist 83
Positive relation between dopamine neuron degeneration and metabolic connectivity disruption in the MPTP plus probenecid mouse model of Parkinson's disease 83
NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease article 78
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 76
RECEPTOR ANTAGONISTS IMPROVE AKINESIA AND SENSORY-MOTOR DEFICITS IN THE 6-HYDROXYDOPAMINE MODEL OF PARKINSON S DISEASE 71
Behavioural characterization of engrailed mutant mice as model of Parkinson's disease 70
PRIMING OF 6-HYDROXYDOPAMINE-LESIONED RATS WITH L-DOPA OR QUINPIROLE RESULTS IN AN INCREASE IN DOPAMINE D1 RECEPTOR-DEPENDENT CYCLIC AMP PRODUCTION IN STRIATAL TISSUE 68
Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson's disease 68
Lack of rhes increases mdma-induced neuroinflammation and dopamine neuron degeneration: Role of gender and age 66
C-FOS EXPRESSION AS A MOLECULAR MARKER IN CORTICOTROPIN-RELEASING FACTOR-INDUCED SEIZURES 65
ADENOSINE A2A ANTAGONISTS AND PARKINSON S DISEASE: NEW FINDINGS ON PARKINSONIAN TREMOR 62
ADENOSINE A2A RECEPTOR AGONISTS INCREASE FOS-LIKE IMMUNOREACTIVITY IN MESOLIMBIC AREAS 60
. Interaction between metabotropic adenosina A2A and glutamate MGLU5 receptors in parkinsonian-like muscle rigidity and tremor 60
Fos expression induced by olanzapine and risperidone in the central extended amygdala 58
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson's Disease 56
Involvement of the protein ras homolog enriched in the striatum, rhes, in dopaminergic neurons' degeneration: Link to parkinson's disease 55
Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems 55
DIFFERENTIAL INDUCTION OF FOS-LIKE-IMMUNOREACTIVITY IN THE EXTENDED AMYGDALA AFTER HALOPERIDOL AND CLOZAPINE 53
Decreased striatal adenosine extracellular levels and increased A2A receptors mRNA after dopamine denarvation 53
Symptomatic efficacy of mucuna pruriens seed extract in rodent model of Parkinson s disease 53
A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A(2A) Receptor Antagonists 52
Extract from Nasco pomace loaded in nutriosomes exerts anti-inflammatory effects in the MPTP mouse model of Parkinson's disease 52
Sensitizzazione alla caffeina e sensitizzazione crociata all'amfetamina in ratti lesi con 6-idrossidopamina: studio comportamentale e biochimico 51
SUBCHRONIC-INTERMITTENT CAFFEINE AMPLIFIES THE MOTOR EFFECTS OF AMPHETAMINE IN RATS 50
Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia 50
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease 49
Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of parkinson's disease 47
Neurobiology of Parkinson's Disease 47
Influence of Age and Genetic Background on Ethanol Intake and Behavioral Response Following Ethanol Consumption and During Abstinence in a Model of Alcohol Abuse 46
BEHAVIOURAL CHARACTERIZATION OF ENGRAILED MUTANT MICE AS MODEL OF PARKINSON S DISEASE. 45
'Priming' to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message 45
Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease 45
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 45
DOPAMINE-DEPENDENT BEHAVIOURAL STIMULATION BY NON-PEPTIDE DELTA OPIOIDS BW 373U86 AND SNC 80: 3. FACILITATION OF D1 AND D2 RESPONSES IN UNILATERALLY 6-HYDROXYDOPAMINE-LESIONED RATS 44
MDMA ADMINISTRATION DURING ADOLESCENCE EXACERBATES MPTP-INDUCED COGNITIVE IMPAIRMENT, NEURODEGENERATION AND NEUROINFLAMMATION IN MOTOR, LIMBIC AND CORTICAL AREAS 44
Rhes counteracts dopamine neuron degeneration and neuroinflammation depending on gender and age 44
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway 43
EFFICACY OF RASAGILINE ON PROGRESSIVE DOPAMINE NEURON DEGENERATION AND NEUROINFLAMMATION IN A CHRONIC MPTPP MODEL OF PARKINSON'S DISEASE 43
Adenosine A(2A) receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. 42
Cross-sensitization between caffeine and amphetamine but not cocaine-induced locomotor behavior 41
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A(2A) receptor antagonist 41
A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease 41
Role of adenosine A(2A) receptors in motor control: relevance to Parkinson's disease and dyskinesia 37
ADENOSINE A2A RECEPTOR ANTAGONIST TREATMENT OF PARKINSON S DISEASE. In The basal ganglia pathophysiology: recent advances 36
Novel therapeutic strategy for the control of dyskinesia in the therapy of Parkinson's disease 36
Neurofarmacologia nel trattamento della Malattia di Parkinson e nuovi approcci farmacologici 36
Caffeine consumption and changes in the function of dopaminergic transmission: Evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 35
Therapeutic potential and antidyskinetic activity of the combined antagonism of adenosine A2A receptors and stimulation of 5HT1A/1B receptors in models of Parkinson's disease: acute and chronic studies. 35
A2A receptor antagonists improve akinesia and sensory-motor deficits in the 6-hydroxydopamine model of Parkinson's disease 35
INDUCTION OF FOS-LIKE IMMUNOREACTIVITY IN THE CENTRAL EXTENDED AMYGDALA BY ANTIDEPRESSANT DRUGS 34
A novel therapeutic strategy to prevent the onset of dyskinesia in models of Parkinson's disease: acute and chronic studies. 34
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 33
Model of dyskinesia in 6-hydroxydopamine-lesioned rats: validity of sensitization in turning behaviour and abnormal involuntary movements. 33
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 32
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats 32
Adenosine A2A receptor antagonists as drugs for symptomatic control of parkinson's disease in preclinical studies 32
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 32
Farmaci Antiparkinsoniani ed Attivi in altri disturbi motori 32
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists 31
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats 31
MOTOR STIMULANT EFFECTS OF THE ADENOSINE A2A RECEPTOR ANTAGONIST SCH 58261 DO NOT DEVELOP TOLERANCE AFTER REPEATED TREATMENTS IN 6-HYDROXYDOPAMINE-LESIONED RATS 31
M. Morelli, N. Simola, A. Pinna, S. Pontis 31
Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses 30
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 30
ENGRAILED MUTANT MICE AS MODEL OF PARKINSON S DISEASE: BEHAVIOURAL CHARACTERIZATION. LIMPE 29
Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry 29
INTERACTION BETWEEN DOPAMINE AND ADENOSINE A2A RECEPTORS AS A BASIS FOR THE TREATMENT OF PARKINSON'S DISEASE 29
Symptomatic and neuroprotective effects of A2A receptor antagonists in Parkinson's disease 29
Interaction between antagonists of adenosine A2A receptors and agonists of serotonin 5-HT1A/B receptors: a novel therapeutic strategy for the control of dyskinesia in the therapy of Parkinson's disease 29
Blockade of NMDA receptors differentially affects D-1 and D-2 mediated turning behavior in the 6-hydroxydopamine model of Parkinson 29
Behavioural Correlates of Dopaminergic Agonists' Dyskinetic Potential in the 6-OHDA-Lesioned Rat 29
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. 29
MODULATORY ROLE OF ADENOSINE A2A RECEPTORS AS BASIS FOR THE USE OF A2A ANTAGONISTS IN THE TREATMENT OF PARKINSON S DISEASE 29
EVALUATION OF LOW AND HIGH DYSKINETIC POTENTIAL OF DOPAMINE AGONIST DRUGS IN THE RAT 6-OHDA MODEL OF PARKINSON S DISEASE 28
DOPAMINE AND ADENOSINE RECEPTOR INTERACTION AS BASIS FOR THE TREATMENT OF PARKINSON'S DISEASE 28
L-Dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors 28
Different patterns of behavior and gene expression induced by chronic L-dopa and A(2A) antagonists plus L-DOPA treatments in 6-hydroxydopamine lesioned rats 27
A novel therapeutic strategy for the prevention of the onset of dyskinesia in the therapy of Parkinson's disease 27
ATTENUATION OF MPTP-INDUCED NEURODEGENERATION BY NCX 2216, A NITRIC OXIDE-RELEASING DERIVATIVE OF FLURBIPROFEN 27
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 27
Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions 27
SENSITIZATION TO TURNING BEHAVIOUR AND ABNORMAL INVOLUNTARY MOVEMENTS IN 6-HYDROXYDOPAMINE LESIONED RATS AS MODELS OF DYSKINESIA. 27
Assessment of Symptomatic and Neuroprotective Efficacy of Mucuna Pruriens Seed Extract in Rodent Model of Parkinson's Disease 27
BLOCKADE OF A2a ADENOSINE RECEPTORS POSITIVELY MODULATES TURNING BEHAVIOUR AND c-FOS EXPRESSION INDUCED BY D1 AGONISTS IN DOPAMINE-DENERVATED RATS 27
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 26
Evaluation of drugs acting on CB1-A2A receptor oligomers in rat models of Parkinson's disease 26
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 26
Sensitisation in turning behaviour and abnormal involuntary movements in 6-hydroxydopamine lesioned rats: Influence of the environment in which tests are performed 26
Caffeine consumption and Changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine. Published in Advances in psychology research 26
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioural and biochemical characterization as an antiparkinsonian drug 26
Behavioral and biochemical characterization as antiparkinsonian drug of the new adenosine A2A antagonist 8-ethoxy-9-ethyladenine 25
CHANGES IN THE EXPRESSION OF TONIC AND PHASIC NEUROCHEMICAL MARKERS OF ACTIVITY IN A RAT MODEL OF L-DOPA INDUCED DYSKINESIA 25
FATE OF (D-ALA2)-DELTORPHIN-I-LIKE IMMUNOREACTIVE NEURONS IN 6-HYDROXYDOPAMINE LESIONED RAT BRAIN 25
FARMACI ANTIPARKINSONIANI ED ATTIVI IN ALTRI DISTURBI MOTORI, vol. 30 del Trattato di Farmacologia 25
Behavioral, Neurochemical, and Electrophysiological Changes in an Early Spontaneous Mouse Model of Nigrostriatal Degeneration 25
SENSITIZATION TO TURNING BEHAVIOUR AND ABNORMAL INVOLUNTARY MOVEMENTS IN 6-HYDROXYDOPAMINE LESIONED RATS: INHFLUENCE OF THE ENVIRONMENT IN WHICH TESTS ARE PERFORMED 24
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. 24
Neuroadaptive changes in striatum and substantia nigra reticulata associated with a dyskinetic L-DOPA treatment are not induced by the low dyskinetic drug ropinirole 24
Totale 5.100
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.758
article - articoli 11.812
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.612
Totale 32.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20244 0 0 0 0 0 0 0 0 2 0 1 1
2024/20252.274 6 11 162 85 674 134 40 66 33 62 543 458
2025/20264.108 286 423 453 541 612 156 612 286 266 265 208 0
Totale 6.386